Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18808193 | 0.81 | CCR1 (0.36) | HDAC1ADORA2AKDM4E | |
| SCHEMBL16523823 | 0.80 | HDAC1 (0.36) | HDAC1ADORA2A | |
| SCHEMBL26803770 | 0.80 | RAB9A (0.33) | RAB9AALDH1A1NPC1LOXL2POLB | |
| SCHEMBL210731 | 0.80 | GBA1 (0.35) | HDAC1ADORA2ARAB9AALDH1A1NPC1 | |
| SCHEMBL10272808 | 0.79 | ADORA2A (0.38) | HDAC1ADORA2ARAB9ANPC1L3MBTL1 | |
| SCHEMBL210170 | 0.76 | HDAC1 (0.35) | HDAC1ADORA2A | |
| SCHEMBL29754040 | 0.73 | TSHR (0.46) | RAB9AALDH1A1NPC1LOXL2POLB | |
| SCHEMBL701703 | 0.73 | TSHR (0.46) | RAB9AALDH1A1NPC1LOXL2POLB | |
| SCHEMBL25568917 | 0.71 | ALDH1A1 (0.36) | RAB9AALDH1A1NPC1LOXL2POLB | |
| SCHEMBL15499726 | 0.69 | LOXL2 (0.36) | RAB9AALDH1A1NPC1LOXL2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885ADORA2A 4077/4885RAB9A 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.